Biocon Limited Recruitment 2019- : Biocon Limited Recruitment 2019 for the position of Program Management- Insulin Devices .Please go through following summary of vacancy. Please check at bottom of the this Summary of vacancy for more details and apply on source web page.
|Post Name||Program Management- Insulin Devices|
|Salary||Not Disclosed by Recruiter|
|Time & Venue||
Opening date: 16/07/2019
Job Description:*To drive the project end to end for Insulin devices. To be accountable for the budgeting of the entire program. To coordinate with various stakeholder across business, drive projects. Keep a tight control on the program timelines and assist management and leadership team in the execution of the device program. Be proactive in assessing road blocks in the projects. Partner interaction will be a major part of the role. Exposure to areas of Market research and competitive intelligence is preferable. MS Excel, power point and project are additional skill expected. Evaluating any New RFQ in detail to understand the customer requirements and request for all the necessary approvals to work on the quote. Create and update project action trackers to track and monitor all the action items related to each of the Project. Lead all the communications and meetings inter-department and also intra-department in the plant. Prepare detailed Capex for all the internal or proprietary projects.
About Company : Biocon is Asia’s premier biopharmaceutical company that is driven by the vision to make a difference to global healthcare through improved access to high quality, life-saving biotherapeutics by making them affordable for patients across the world. We have evolved from manufacturing pharmaceuticals like statins and immunosuppresants, to discovering, developing and producing biologics in chronic therapies such as diabetes, oncology and immunology for global markets. This has translated into a diversified and differentiated pipeline of fermentation-derived complex generics, biosimilars that include insulins and monoclonal antibodies, and novel biologics.